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Bone Lead, Hypertension, and Lead
Nephropathy
by Richard P. Wedeen*
There is considerable clinical evidence that excessive lead absorption causes renal failure with
hypertension and predisposes individuals to hypertension even in the absence of detectable renal
failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may
reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis
population. In these patients, bone lead levels were four times higher than in unexposed cadavers (6
pg/g wet weight) and approximated levels found in lead workers (30 pg/g ). At present, the most
reliable index of the body lead burden is the CaNa2 EDTA lead mobilization test. In vivo tibial X-ray-
induced X-ray fluorescence (XRF) is a more practical noninvasive technique for assessing bone lead,
which should find widespread application as a diagnostic tool and for epidemiologic studies.
Exposure Levels in Adults
The role of environmental lead in the induction of
hypertension and renal disease in adults has received
little attention since measurements in the nineteenth
century first suggested a relationship between lead,
high blood pressure, and disease of the kidneys (1).
There is now considerable evidence that excessive lead
absorption causes slowly progressive renal disease and
that lead predisposes individuals to hypertension even
in the absence ofdetectable renal failure.
The health effects of lead in adults has gone largely
unrecognized because of conventional reliance on the
blood lead measurement (PbB) using criteria for
normal based on symptomatic acute poisoning. Over
90% ofthe body burden oflead is stored in bone and has
a biological half-life approximating several decades (2).
Cumulative lead absorption is best assessed at present
by the EDTA lead mobilization test (3). The chelation
test correlates well with bone lead concentrations
determined by direct measurement and thus provides
agood estimate ofthe body lead burden.
It is useful to consider the health consequences of
lead in four, often overlapping, exposure categories
(Iable 1).
Classical Acute Lead Intoxication
Massive lead absorption over a brief period of time
induces abdominal colic, peripheral neuropathy,
mental dysfunction, seizures, and anemia. These
symptoms of acute poisoning have been recognized for
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2000 years. In adult lead workers, transient hyper-
tension is common during the acute phase. In chil-
dren, the kidneys leak amino acids and other circu-
lating substances normally reabsorbed by the proxi-
mal tubule (Fanconi syndrome). Blood lead levels are
more than 70 ,ug/dL during the acute episode. Symp-
toms are reversed by chelation therapy or termination
ofexposure.
Chronic Industrial Exposure
Continuous lead absorption at levels insufficient to
produce the hallmarks of acute intoxication, increases
the body burden of lead and can induce hypertension,
interstitial nephritis, and behavioral abnormalities
after a few years. Blood lead levels depend on the prox-
imity to recent exposure and may be only modestly
elevated at the time clinical symptoms are recognized;
PbB is from 30 to 80 gg/dL. Nonoccupationally ex-
posed adult males have mean PbB levels of about 15
,ug/dL (4). Prolonged exposure in the workplace pro-
duces bone lead stores that are more than four times
that of nonoccupationally exposed individuals. Tran-
siliac bone biopsy lead levels averaged 30 gg/g in 22
Belgian lead workers (5). The mean chelatable lead in
these men was 1923 ig/3 days. In individuals with-
out unusual exposure, transiliac bone lead levels
averaged 6 jg/g.
Sporadic Exposure
Increased total body lead burdens result from inter-
mittent (usually unrecognized) exposure in the ab-
sence of symptoms of acute intoxication. Sporadic highR. P. WEEDEN
Table 1. Levels oflead exposure.
Blood lead, Iliac [Pbl,
Type ofexposure Description Source Symptoms pg/dL pg/g
Acute Massive Pica Seizures 70-200 Time dependent
Rapid Fumes Neuropathy
Accident Mental
Moonshine Fanconi syndrome
Transient hypertension
Chronic High Workplace Hypertension 30-80 > 25
Persistent Renal
Mental
Sporadic Moderate Paint Hypertension 20-50 > 20
Occasional Glazes Renal
Workplace Mental
Moonshine
Water
Ambient Low Gas Hypertension 10-25 5
Persistent Water IQ
Food
exposure derives from occasional work situations; It is the third level, sporadic and unrecognized lead
from contaminated food, water, or alcoholic drinks; exposure, that we have studied over the last 7 years.
from the dust of old paint chips; and the leaching of None ofthese patients was aware of excessive past lead
lead from improperly prepared glazes. It has recently absorption. None had suffered the symptoms of acute
been found that dangerous quantities of lead can leach lead intoxication and none had a diagnosis of lead
through unleaded glazes from painted surface decora- nephropathy prior to these studies.
tions on ceramic (Donald M. Wallace, personal com- Body lead burdens were assessed with the EDTAlead
munication). Sporadic high lead absorption may mobilization test in 21 hypertensives with renal fail-
cause body burdens to increase to levels seen in lead ure (serum creatinine > 1.5 mg/dL), 27 hypertensives
workers after 1 to 5 years. Transiliac lead levels exceed without renal failure, and in 22 patients with renal
20 gg/g and the PbB is 20 to 50 gg/dL. The frequency failure not due to lead (6). The chelation test was
of sporadic exposure may approach 1%, approximating performed by giving 1 g CaNa2EDTA IM twice, 12 hr
the frequency of blood lead levels over 30 ,ug/dL in the apart, and collecting urine for measurement of lead
general population (4). chelate and creatinine excretion for the subsequent 3
days. To each 5 mL of EDTA, 1 mL of 2% lidocaine was
added. The mean chelatable lead in the patients with
Ambient Lead Exposure hypertension and renal failure was significantly
higher than that of hypertensives without renal fail-
This is the ubiquitous lead exposure that most of the ure, 860 ± 30 versus 340 ± 39 ig Pb/3 days, respectively
world encounters. The effect of normal lead absorption (Table 2). Chelatable lead was also higher in hyperten-
on blood pressure is the subject of other papers in this sives with renal failure than in control patients with
meeting. Universal exposure makes it difficult to comparably diminished renal function due to another
identify appropriate control groups. Consequently, the identifiable etiology (440 ± 50 ,ug/3 days). The control
generally accepted upper limit of normal for the EDTA renal failure group demonstrates that renal failure per
lead mobilization test (650 ,ug lead chelate/day) is se does not increase mobilizable lead. Moreover, the
undoubtedly too high. Clinical studies of small groups known duration of hypertension in the patients with
to detect the role of lead in hypertension are, therefore, renal failure (7 years) was half of that of hypertensives
likely to be unproductive. with preserved renal function (14 years). The in-
Table 2. Patients with essential hypertension.a
Serum Urinary Blood EDTAtest
No. of Age, creatinine, protein, lead, results,
Category patients years mg/dL mg/day pig/dL jig Pb/3 days
No renal disease 21 55 ± 2 1.2 ± 0.1 257 ± 67 18± 2 340 ± 39
Renal disease 27 57 ± 2 3.2 ± 0.5 642 ± 133 19± 4 860 ± 10
p value NSb < 0.001 < 0.001 NS < 0.001
Renal controlsc 22 54 ± 3 3.4 ± 0.5 1971 ± 779 15 ± 2 440 ± 50
aValues expressed as mean ± SEM.
bNS, not significant.
cRenal controls were patients with renal failure ofnonlead causes.
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creased duration of elevated pressure in patients
without renal failure indicates that hypertension was
not the cause, but the result of renal disease. Although
these patients had been considered to have essential
hypertension prior to chelation testing, the study
indicates that lead played an etiologic role in the
development of hypertension and renal failure in
some.
This interpretation is founded on the assumption
that the accessibility ofbone lead stores to the chelating
agent is essentially equivalent in hypertensive and
control renal failure patients. Studies recently per-
formed in DeBroe's laboratory at the University of
Antwerp support this view (5). One hundred fifty-
three transiliac bone biopsies obtained for aluminum
studies from patients with end-stage renal disease were
analyzed for lead and calcium. The mean bone lead in
these dialysis patients was 6 ,ug/g, indicating that
bone lead is not elevated by end-stage renal disease and
that the increased mobilizable lead in hypertensives
with renal failure is, therefore, not due to increased
lead storage induced by renal failure. Moreover,
patients with analgesic nephropathy, a form of
interstitial nephritis that can be accurately diagnosed,
had low levels of iliac lead (mean = 4 gg/g). Interstitial
nephritis therefore does not appear to induce a unique
form of uremic osteodystrophy characterized by
increased bonelead stores.
Five percent of the French, German, and Belgium
dialysis patients studied in Belgium had iliac bone
lead levels comparable to those found in lead workers:
20 tg/g wet weight. Bone histomorphometry in the
dialysis patients with elevated bone leads did not differ
from that in dialysis patients with low bone leads
confirming the absence of unique bone disease. These
data suggest that up to 5% of the European dialysis
population have unsuspected excessive lead absorption
as the cause, or contributing cause, of their end-stage
renal disease (5).
Additional studies of 24 Belgian lead workers
demonstrated that the chelation test provides a good
estimate ofbone lead. The lead content oftransiliac bone
biopsies compared to the EDTA lead mobilization test
gave a linear regression correlation coefficient (r) of
0.87. Taken together, these studies provide criteria for
the diagnosis of excessive cumulative lead absorption
directly from bone biopsies, which may prove useful
in functionally anephric patients.
Evidence was also obtained in Antwerp indicating
that measurement of the Pb:Ca ratio in bone is more
reliable than the absolute bone lead concentration. Bone
Pb:Ca shows less variability than the [Pb], presumably
because of the variable quantity of noncortical bone in
the biopsy specimens. In addition, the effect of
demineralization due to uremic osteodystrophy is
minimized when the Pb:Ca ratio is used.
The Pb:Ca ratio has another advantage. It is precisely
Pb:Ca that is most accurately measured by the new
technique of in vivo tibial X-ray induced X-ray
fluorescence (XRF) using characteristic K X-rays from
lead, elicited by a 109Cd radioactive source (7,8). This
technique for assessing bone lead content eliminates
the need for injecting EDTA and for urine collections
and thus is a more practical diagnostic tool particu-
larly for epidemiologic studies. The main limitation of
XRF using K fluorescent X-rays may be the difficulty
in measuring bone lead levels encountered in the
normal population (< 10 ,ug/g). XRF can detect bone
lead levels of 20 ,ug/g or higher with good precision
and therefore is suitable for detecting individuals at
risk from industrial level lead absorption.
In 21 unselected renal patients from New Jersey
tibial lead (determined by in vivo XRF) and chelatable
lead levels fell within the expected range (95% confi-
dence limits) found by direct transiliac bone biopsy in
the 24 patients from Antwerp who had EDTA lead mo-
bilization tests (Fig. 1). XRF therefore appears to be
suitable for determining the risk of renal disease in the
general population and in dialysis patients, an un-
dertaking that is essential for public health planning.
These studies provide insight into the question: How
much lead is too much? The normal population has an
iliac lead concentration of about 5 ,ug/g compared to >
20 ,ug/g in lead workers. A fourfold increased in bone
lead in occupational as compared to ambient exposure
has also been reported by Barry (3). Thus, a fourfold
increase in lead absorption places an individual at the
same risk as the lead worker for lead-induced hyper-
tension, renal disease, and behavioral abnormalities.
The total body lead of a 70-year-old man (whose bone
lead is 5 ,ug/g) approximates 200 mg (9,10). Conse-
quently, the absorption of500jg excess Pb per day for 5
years (182 mg/year) turns a normal body lead burden
into that of an industrial lead worker. Such absorption
can easily be acquired from lead leached from ceramics,
from contaminated water, or from pulverized old lead
paint chips. Current FDA regulations permit 5 ppm to
be leached from ceramics. This would provide enough
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FIGURE 1. In vivo tibial XRF [Pb] and chelatable Pb (EDTA test) in 21
New Jersey VA patients (M) plotted within 95% confidence limits of
24 Belgian patients (including lead workers) in whom bone lead was
measured by atomic absorption spectroscopy from transiliac
biopsies. (Iliac lead conversion factor to tibial lead = 1.7.)
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lead to reach the usual adult maximum body burden
in 1 year. Individuals who consume 1 L a day of li-
quid containing 5 ppm Pb would accumulate almost
200 mg Pb a year, assuming 10% absorption. The risks
to adults of sporadic high lead absorption from such
unrecognized sources must be addressed by the medi-
cal, public health, and lead manufacturing commu-
nities.
This work was supported by the Veterans' Administration Medical
Research Service.
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